Sclerostin antibody | AbD09097_h/mIgG2a

100% Secure


Human anti Sclerostin:Preservative Free

Product Type
Monoclonal Antibody
Clone
AbD09097_h/mIgG2a
Isotype
IgG2a
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
HCA230Z C FN 0.1 mg
Human anti sclerostin, clone AbD09097_h/mIgG2a specifically recognises human and mouse sclerostin, also known as SOST. Sclerostin is a secreted extracellular matrix protein that is expressed at low levels in bone, bone marrow and cartilage. It may also be detected in other tissues such as kidney and liver. Sclerostin is important in the negative regulation of bone growth with mutations in the sclerostin gene resulting in conditions associated with high bone mass such as sclerosteosis and van Buchem disease. Sclerostin research may facilitate the development of future treatments for diseases associated with bone loss such as osteoporosis (Papapoulos 2011).

Sclerostin mediates its inhibitory effect on bone formation by directly blocking the Wnt signaling pathway. In addition, it has been reported that sclerostin may associate with intracellular bone morphogenic protein 7 (BMP7), and block its secretion in osteocytes (Krause et al. 2010).

Clone AbD09097_h/mIgG2a has been demonstrated to block the binding of sclerostin to the Wnt co-receptors, low density lipoprotein receptor-related protein (LRP) 5 and LRP6 on KS483 cells. In a BAT-luc reporter assay, clone AbD09097_h/mIgG2a showed a significant rescue of the inhibition by Sclerostin on the Wnt3a induced BAT-luc activity. Clone AbD09097_h/mIgG2a was also able to rescue the inhibition by sclerostin on Wnt3a-induced AXIN2 mRNA expression and the sclerostin-mediated inhibition of alkaline phosphatase activity induced by Wnt3a (van Dinther et al. 2013).

Clone AbD09097_h/mIgG2a is a fully human/mouse chimeric antibody, developed from the inhibitory Fab antibody AbD09097(van Dinther et al. 2013).

Product Details

Target Species
Human
Species Cross-Reactivity
Target SpeciesCross Reactivity
Mouse
N.B. Antibody reactivity and working conditions may vary between species.
Product Form
Chimeric human/mouse IgG2a antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. In this chimeric antibody, the VH and VL domains are human sequence, and all the antibody constant domains are from mouse. Anti-mouse Fc specific antibodies are recommended as secondary detection reagents. This antibody is supplied as a liquid.
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
None present
Immunogen
Recombinant human and murine sclerostin.
Affinity
The monovalent intrinsic affinity of AbD09097_h/mIgG2a was measured as Kd = 253 nM to human sclerostin and Kd = 49 nM to mouse sclerostin. Affinity measurements were performed using the ProteOn device (Bio-Rad) on recombinant sclerostin immobilized on an activated ProteOn GLC sensor chip.
Approx. Protein Concentrations
Total protein concentration 0.5 mg/ml

Storage Information

Storage
Store at -20oC only.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.
Shelf Life
12 months from date of despatch

More Information

UniProt
Q9BQB4 Related reagents
Q99P68 Related reagents
Entrez Gene
Sost Related reagents
SOST Related reagents
GO Terms
GO:0005515 protein binding
GO:0001503 ossification
GO:0016055 Wnt receptor signaling pathway
GO:0008201 heparin binding
GO:0030514 negative regulation of BMP signaling pathway
GO:0090090 negative regulation of canonical Wnt receptor signaling pathway
GO:0030279 negative regulation of ossification
GO:0031333 negative regulation of protein complex assembly
GO:2000054 negative regulation of Wnt receptor signaling pathway involved in dorsal/ventral axis specification
Acknowledgements
Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
Licensed Use
For in vitro research purposes only, unless otherwise specified in writing by Bio-Rad.
Regulatory
For research purposes only

Applications of Sclerostin antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Functional Assays
Immunohistology - Frozen
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual

Application Based External Images

Functional Assays

Product Specific References

References for Sclerostin antibody

  1. van Dinther, M. et al. (2013) Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.
    PLoS One. 8 (4): e62295.
  2. Boschert, V. et al. (2015) Crystallization and preliminary X-ray crystallographic analysis of the sclerostin-neutralizing Fab AbD09097.
    Acta Crystallogr F Struct Biol Commun. 71 (Pt 4): 388-92.
  3. Boschert V. et al. (2016) The sclerostin-neutralizing antibody AbD09097 recognizes an epitope adjacent to sclerostin's binding site for the Wnt co-receptor LRP6
    Open Biology. 6 (8): 160120.

Further Reading

  1. Back, J.W. et al. (2012) Selecting highly structure-specific antibodies using structured synthetic mimics of the cystine knot protein sclerostin.
    Protein Eng Des Sel. 25 (5): 251-9.
  2. Krause, C. et al. (2010) Distinct Modes of Inhibition by Sclerostin on Bone Morphogenetic Protein and Wnt Signaling Pathways.
    J Biol Chem. 285(53): 41614-26
  3. Papapoulos, S.E. (2011) Targeting sclerostin as potential treatment of osteoporosis
    Ann Rheum Dis. 70 (1): 119-22